Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients

Status unconfirmed

Conditions studied: Alzheimer Disease

In brief

The study will determine if Therapeutic Plasma Exchange removes RNA biomarkers associated with Alzheimer's Disease and how quickly those biomarkers reappear after treatment.

Key facts

Study ID

NCT06079827

Run by

MaxWell Clinic, PLC

People needed

43

Starts

2022-03-22

Expected to finish

2025-09-01

Last updated by the study team

2023-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is scheduled to undergo their first TPE Procedure for a diagnosis of Alzheimer's Disease or previous mental/cognitive impairment
• Mentally capable of understanding and completing informed consent for the study.

You may not qualify if…

• Subject is unable or failed to return/provide blood specimen on days seven (7), fourteen (14) , twenty-one (21), and twenty-eight (28) (plus or minus 1 day on follow up draws) post plasma exchange
• Subject is unable to provide informed consent.

Where it is running

• The MaxWell Clinic — Brentwood, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.